Merck, Luminex Partner to Advance Companion Test for Alzheimer's Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Merck and Luminex said they will work together to develop a companion test for Merck's investigational BACE inhibitor for Alzheimer's disease, MK-8931.

The diagnostic, which will operate on Luminex's xMAP platform, will be used to stratify patients into clinical trials involving MK-8931. According to the companies, Luminex will be in charge of developing, garnering regulatory approval, and commercializing the companion test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.